Search filters
Filters
Clear All

Phase

  • 13
  • 1
  • 10
  • 6
  • 175
  • 206
  • 166
  • 1
  • 5
  • 200

Found 206 cc-cancer-center trials

A listing of cc-cancer-center medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 29123: CAMBRIA-1: A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy

99 years and younger
All genders
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy for at …
Learn More

UPCC 21123 A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd

99 years and younger
All genders
A Global, Single Arm, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd. The ARX788 will be administered every 3 weeks (Q3W) intravenous (IV) infusion. We would like to rely on WCG IRB as the IRB of record for this study.
Learn More

UPCC 36423: Resilience in Older Adults with Leukemia Receiving Initial Treatment: the ROAR-1 Study

99 years and younger
All genders
The purpose of this study is understand changes in cognition, physical abilities, and quality of life of individuals receiving venetoclax-based chemotherapy.
Learn More

NRG-BR009 A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score

99 years and younger
All genders
To determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 …
Learn More

S1900A: A Phase II Study of Rucaparib in Patients with Genomic LOH High And/Or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)

99 years and younger
All genders
This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed …
Learn More

UPCC 01524: Brightline-4: A Phase III open-label, single-arm, multi-center study to assess the safety and efficacy of brigimadlin (BI 907828) treatment in patients with treatment-naïve or pre-treated advanced dedifferentiated liposarcoma

99 years and younger
All genders
The purpose of this study is to find out whether brigimadlin (BI 907828) is tolerated by and helps people with DDLPS. Brigimadlin is a so-called MDM2 inhibitor that is being developed to treat cancer. We would like to rely on Advarra as the IRB of record for this study.
Learn More

UPCC 29421: Administration of HIV-specific T cells to HIV+ Patients Receiving High Dose Chemotherapy Followed by Autologous Stem Cell Rescue -Auto-RESIST

99 years and younger
All genders
Were doing this study to see if a type of cells called HST-NEETs can help the body fight HIV. HST-NEETs are cells made from immune cells that have been treated and grown in a lab. This is a phase 2 study.
Learn More

A011801 The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with

99 years and younger
All genders
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer.
Learn More

ECOG EA6174 A Phase III Randomized Trial Comparing Adjuvant MK- 3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

99 years and younger
All genders
This phase III trial studies how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere …
Learn More

UPCC 11220: BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer

99 years and younger
All genders
The study will enrollsubjects who have undergone surgery for stage II or III colorectal cancer and who have residual FFPE tissue available will provide FFPE and whole blood samples. Subjects will receive SIGNATERA test results and may be recommended for adjuvant chemotherapy or observation by their treating clinician.The study also …
Learn More
121 - 130 of 206